China Tracker - Details for Shengtai Pharmaceutical (SGTI)

 Shengtai Pharmaceutical
Shares Outstanding (MRQ): 9.58 mill
New Shares / Dilution (TTM): 0.00 mill0.00%
Cash (MRQ): 2.24 mill238.13%
Account Receivables (MRQ): 11.60 mill1,235.35%
Account Receivables (Q/Q): -2.46 mill-17.50%
Long-Term Debt (MRQ): NO DEBT
Revenue Growth (Q/Q): -15.00% 
Revenue Growth (Y/Y): 41.75%
Net Income Growth (Q/Q): -14.51% 
Net Income Growth (Y/Y): 135.67%
EPS Growth (Y/Y): 135.67%
Net Margin (Q/Q): 5.5% (5.5%)0.00% 
Net Margin (Y/Y): 5.5% (3.3%)2.20% 
EPS | P/E (2 MRQ Projection): $1.040.09
CFPS | P/CF (2 MRQ Projection): -$0.40-0.25
Price/Sales (2 MRQ Projection): 0.01
Price/Book (MRQ): 0.02
Auditor: Kabani & Company 
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2011-02-15): $0.900.11
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2007-05-15 

 Business Outlook

With our performance to date during the 2011 fiscal year, we are very confident and proud to say that both the net revenue and net income will increase greatly for the fiscal year 2011 compared to fiscal year 2010. As we look further into the fourth quarter of our fiscal year 2011, we expect our cornstarch manufacturing facility be utilized at around 85% of capacity by the end of December 31, 2011. The newly expanded cornstarch manufacturing facilities will help us to satisfy the increasing demand of our cornstarch products and byproducts. We have already built relatively large back orders for our glucose and cornstarch products. In order to continually stabilize our gross profit margin, we will continue to construct additional storage facilities to better control the impact of fluctuating corn prices. Looking forward, we are also confident with our cash position, which is enhanced by the increased sales and good accounts receivable collection. In the coming year, we will focus on providing high quality products as well as continue searching for higher profit high-tech products.

(Source: PR Newswire, 2011-05-16)

For the second half of fiscal year 2011, we expect sales of our glucose, cornstarch and other products will continue to grow in both domestic and international markets. As we look further into the second half of our fiscal year 2011, we expect our newly expanded cornstarch manufacturing facility will be utilized over 50% by the end of fiscal year 2011. The newly expanded cornstarch manufacturing facilities will help us to satisfy the increasing demand of our cornstarch products and byproducts. We have already built relatively large back orders for our glucose and cornstarch products. In order to stabilize our gross profit, we have continued to construct additional storage facilities to better control the impact of fluctuating corn prices. Looking forward, we are also confident with our cash position, which is enhanced by the increased sales and good accounts receivable collection. In the coming year, we will focus on providing high quality products as well as continue searching for higher profit high-tech products.

(Source: PR Newswire, 2011-02-14)

Fiscal Year 2011 guidance in 8-K filing: revenue for FY 2011 ending June 30, 2011: $180 million (+ 55.25% over FY 2010), gross margin unchanged at 15.25% and net income of $10 million (+ 212.5% over FY 2010)

(Source: 8-K Filing, 2010-10-18)

    see all Business Outlook notes

 Investor Presentations
2010-10-18 (HTML)   VIEW
2009-02-17 (Powerpoint)   DOWNLOAD (right click, save as)
SGTI
Healthcare & Drugs
SCORE
15
READ: Score Cards Explained
SAFETY/RISK SCORE
EXTREME RISK
DETAILS: Safety/Risk Model for SGTI
Current Price:  $0.10
F10k Day (2007-07-17): -98.32%$5.80
2009 Close: -95.59%$2.22
2010 Close: -96.63%$2.90
2011 Close: -90.58%$1.04
High (2012-10-03): -96.08%$2.50
Low (2012-06-07): -84.20%$0.62
Exchange: PNK
Market Capitalization: 0.94 mill
Total Shares: 9.58 mill
Float: n/a
Avg Volume: n/a
Last Quarter: 2011-03-31
Revenue (MRQ): 41.69 mill
Net Income (MRQ): 2.31 mill
Op. Cash Flow (MRQ): -2.55 mill
all financial data provided without warranty